These cells are responsible for producing and maintaining the myelin sheath of nerve cells so the GLP-1R agonists, like NLY01, would target mature oligodendrocytes
Weight loss with Ozempic or Wegovy can be effective, but expensive
Codeage Liposomal Glutathione+ Why its on the list: Designed for enhanced absorption, Codeages liposomal formula adds phospholipids and complementary antioxidants
Early trials of retatrutide revealed that users could lose up to a quarter of their body weight in under a year, making it nearly twice as effective as Ozempic
Industry analysts project retatrutide will likely fall in a similar range to tirzepatide, possibly with a premium given its enhanced efficacy profile
AstraZeneca - Building a strong obesity and metabolic disease pipeline Amgen - MariTide showing promising obesity treatment potential Roche - Expanding through strategic acquisitions and obesity-focused programs Pfizer - Continuing development efforts in oral obesity medicines Structure Therapeutics - Advancing next-generation oral GLP-1 candidates Viking Therapeutics - Emerging as a major obesity treatment contender Altimmune - Developing innovative metabolic disease therapies Boehringer Ingelheim - Investing in future cardiometabolic opportunities Why is everyone chasing GLP-1
